Table 1.

Patient characteristics according to miRNA-126 and MVD

Parameter	Number	miRNA-126	p-value	MVD	p-value
	(n = 560) (%)	(n = 560)		(n = 555)
		Median (95% CI)		Median (95% CI)
Sex
Male	241 (43)	2.49 (2.38-2.59)	0.61	10.7 (10.3-11.0)	0.17
Female	319 (57)	2.47 (2.40-2.53)		10.3 (10.0-10.7)
Age, median 74
≥74	280 (50)	2.49 (2.42-2.56)	0.31	10.7 (10.3-11.0)	0.11
<74	280 (50)	2.44 (2.34-2.53)		10.3 (10.0-10.7)
T category
T4	73 (13)	2.20 (2.03-2.42)	0.0004	10.3 (10.0-11.3)	0.59
T3	487 (87)	2.50 (2.44-2.56)		10.3 (10.0-10.7)
Malignancy grade
High*	107 (19)	2.33 (2.17-2.48)	0.01	10.0 (9.3-10.7)	0.03
Medium + Low	453 (81)	2.49 (2.43-2.56)		10.7 (10.3-10.7)
Localisation
Right	286 (51)	2.48 (2.39-2.54)	0.45	10.3 (10.0-10.7)	0.75
Left	274 (49)	2.48 (2.38-2.56)		10.3 (10.0-10.7)
Perforation
Yes	49 (9)	2.36 (2.05-2.42)	0.003	11.0 (10.0-12.0)	0.19
No	511 (91)	2.49 (2.43-2.56)		10.3 (10.0-10.7)
Fixation
Yes	100 (18)	2.36 (2.12-2.47)	0.0009	10.7 (10.3-11.3)	0.15
No	460 (82)	2.50 (2.43-2.57)		10.3 (10.0-10.7)
Lymph nodes a
≥12	251 (45)	2.49 (2.39-2.54)	0.96	10.7 (10.0-11.0)	0.10
<12	306 (55)	2.47 (2.39-2.56)		10.3 (10.0-10.7)
Neuronal invasion
Yes	47 (8)	2.38 (2.16-2.59)	0.66	10.0 (9.0-10.7)	0.29
No	513 (92)	2.48 (2.42-2.53)		10.3 (10.3-10.7)
Vascular invasion
Yes	67 (12)	2.48 (2.31-2.65)	0.81	10.3 (10.0-11.0)	0.98
No	493 (88)	2.48 (2.42-2.53)		10.3 (10.0-10.7)
MSI status
MSI	159 (28)	2.30 (2.17-2.46)	0.003	10.3 (10.0-11.0)	0.83
MSS	401 (72)	2.53 (2.46-2.59)		10.3 (10.0-10.7)

CI: confidence interval; miRNA-126: microRNA-126; MSI: microsatelite instability; MSS: microsatelite stable; MVD: microvessel density.

^aNot assessed for all patients.

*Including mucinous and sigillocellular adenocarcinomas.

Significant p-values are highlighted in bold.